alexa Headache in Buprenorphine Detoxification Treatment | OMICS International | Abstract
ISSN: 2155-6105

Journal of Addiction Research & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Headache in Buprenorphine Detoxification Treatment

Arash Bostani, Nasrin moradian* and Hosein Kasmayi

Neurology Department, Imam Reza Hospital, Kermanshah University of Medical Sciences, Sorkheh-lijeh, Kermanshah, Iran

*Corresponding Author:
Dr. Nasrin Moradian
Neurology Department of Imam reza hospital
Kermanshah University of Medical Sciences
Sorkheh-lijeh, Kermanshah, Iran
Tel: +98-918-3316832
E-mail: [email protected]

Received December 07, 2012; Accepted January 21, 2013; Published February 02, 2013

Citation:Bostani A, moradian N, Kasmayi H (2013) Headache in Buprenorphine Detoxification Treatment. J Addict Res Ther 4:142. doi:10.4172/2155-6105.1000142

Copyright: © 2013 Bostani A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Buprenorphine is a partial mu-opioid receptor agonist that is an effective agent for agonist therapy for opioid addiction and for the management of withdrawal from heroin and other opioids.

Methods: 379 addict patients who admitted for detoxification therapy with buprenorphine were enrolled in the study. Withdrawal scale (using short opiate withdrawal scale) and headache intensity (11-point numerical rating scale) were assessed daily during detoxification course. History of headache, outcome of patients and dose of buprenorphine were recorded also.

Result: 239 patients (63.1%) experienced headache during assessment that 43% of them experienced more severe headaches based on median of pain intensity. Positive history of chronic headache was more common in these patients (81.1% versus 17.8%, p<0.05). During mild headache person-days, dose of buprenorphine was lower and withdrawal scale as higher than other days. We didn’t find any significant difference between mean withdrawal scales and dose of buprenorphine in severe headache days and other days. Incidence of severe headache in dropped out patients was similar to other patients and experience of severe headache was less common in patients who chose buprenophine for maintenance therapy.

Conclusion: We concluded that headache is an important compliant during treatment of opiate addiction with buprenorphine and is not just a symptom of opiate withdrawal.

Keywords

Recommended Conferences
Share This Page
Top